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Abstract 
Synaptic dysfunction and dysregulation of Ca2+ are linked to neurodegenerative processes and 
behavioural disorders. Our understanding of causes and factors involved in behavioural 
disorders and neurodegeneration, especially Alzheimer’s disease, a tau-related disease, is on 
the one hand limited and on the other hand controversial. Here, we reviewed recent data about 
the links between the Ca2+-binding, EF-hand containing cytoskeletal protein Swiprosin-
1/EFhd2 (EFhd2) and neurodegeneration. Specifically, we have summarized the functional 
biochemical data obtained in vitro with use of recombinant EFhd2 protein, and integrated 
them with in vivo data in order to interpret the emerging role of EFhd2 in synaptic plasticity 
and in the pathophysiology of neurodegenerative disorders, particularly involving the 
tauopathies. We have also discussed its functions in actin remodeling through cofilin and 
small GTPases, thereby, linking EFhd2, synapses and the actin cytoskeleton. Expression data 
and functional experiments in mouse and in man have led to the hypothesis that down-
regulation of EFhd2, especially in the cortex, is involved to dementia.  
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Expression of EFhd2 in the nervous system and links to neurodegenerative diseases 
Many genes and proteins have been identified in one tissue type only to be found that they 
have equally important signaling roles in others. Indeed, activated B cells involved in T cell 
dependent immune reactions within germinal centers, express many hitherto thought to be 
neuron-specific genes and reveal long extensions reminiscent of neurites [1]. Hence, although 
of different lineage, immune and nerve cells appear to share common signaling pathways. 
Though swiprosin-1/EFhd2 was first identified in the immune system [2], it has become 
increasingly apparent that EFhd2 has a significant role in the mammalian nervous system, and 
that its function can be linked to several neurological disorders.  
Initial studies showed that EFhd2 is most strongly expressed in the brain [3]. Later, 
EFhd2 could be identified from immunoprecipitation studies of the microtubule associated 
protein tau, from tauopathy transgenic mouse brains [4]. Western blot analysis indicated that 
EFhd2 is expressed in all parts of the brain (brain stem, cerebellum, amygdala, striatum, 
hippocampus, cortex and prefrontal cortex) and at similar levels [4]. It was also reported that 
the tau - EFhd2 interaction was dependent on the stage of neurodegeneration of the tauopathy 
transgenic mouse model (JNPL3), being enhanced as the animals were showing more 
tauopathy; preliminary data also indicated that this could be the case in single cases of 
Alzheimer’s disease (AD) and frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) [4], though follow on work with larger number of AD brains, 
confirmed that EFhd2 and tau could be found in aggregates  [5].  
Our own work has extended our knowledge of where EFhd2 is expressed in the 
mammalian brain and how it changes expression in dementias [6, 7]. Specifically, Brachs et 
al. generated an EFhd2 knockout (KO)/lacZ reporter gene knockin mouse (EFhd2KO) by 
blastocyst injection of commercially available ES cells in which the efhd2 gene had been 
replaced with an in frame lacZ reporter cassette through homologous recombination [8] 
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EFhd2KO mice reveal a dose-dependent increase of lacZ compared to heterozygous mice 
carrying only one mutated allele (EFhd2HT), concomitant with a dose-dependent decrease of 
EFhd2 expression. This indicated that efhd2 expression is haplo-insufficient, at least in this 
system, and that for full efhd2 expression, both alleles need to be active [7]. This mouse strain 
next allowed for the detailed characterization of EFhd2 expression in the mouse brain by 
detecting the presence of β-galactosidase activity, which was confirmed by the use of specific 
EFhd2 antibodies [9] and immunostaining of sections of the brain. EFhd2 expression was 
observed in the pyramidal layers of the cortex, the dentate gyrus, and the CA1-CA2 regions of 
the hippocampus [7]. These findings confirmed previous in situ hybridizations described in 
the Allen brain atlas which had indicated strong efhd2 mRNA expression in neuronal rich 
areas of the brain. White matter regions such as the corpus callosum do not show EFhd2 
expression, again confirming the Allen brain atlas in situ hybridisation and microarray 
studies. In addition, our studies indicated that the EFhd2 protein is more abundant in the adult 
than in the embryonic brain, where it is expressed early in the developing cortex, 
hippocampus and thalamus [7]. 
 As indicated above the increased association of EFhd2 to tau was first postulated to be 
a link with this Ca2+ binding protein and AD, albeit the mouse model that has been used 
carries a mutated human tau protein (tau P301L) which is found in the rare neurodegenerative 
disease FTDP-17 [4]. Initially, FGM’s group’s interest in EFhd2 came from proteomic studies 
to identify proteins that changed expression in mitochondrial dysfunction models of AD and 
specifically to identify synaptic proteins that changed expression (reviewed in [10]). Other 
studies have also indicated potential links of EFhd2 to diseases associated with synaptic 
dysfunction; for example, changes in EFhd2 protein levels have been noted in the prefrontal 
cortex of patients with schizophrenia [11], suicide victims [12], and a mouse model for 
amyotrophic lateral sclerosis/motor neuron disease [13]. Interestingly, in a rat model for AD, 
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low frequency electromagnetic fields partially improved cognitive and pathologic symptoms 
correlating with up-regulation of EFhd2 in the hippocampus [14]. On the other hand, the anti-
inflammatory drug Ibuprofen led to down-regulation of EFhd2 in the hippocampus of mice 
[15].  However, to date the most systematic and largest study (n = 48 brains) that has linked 
EFhd2 expression directly to human dementia, was described in Borger et al. 2014, which 
revealed a significant down-regulation of EFhd2 both at the mRNA and protein level in the 
cortex of AD brain and other dementias including various different types of frontotemporal 
lobar degeneration (FTLD) including FTDP-17 and FTLD-tau with Pick bodies (Pick 
disease), which are all classified as tauopathies [6]. This down-regulation of EFhd2 did not 
appear to correlate with the extent of pathologic tau phosphorylation. Other tantalizing 
potential links between EFhd2 and neurodegeneration have also come from studies which 
have shown that it can bind to the Parkinsonian associated protein LRRK2 [16], and it has 
been shown to be downstream and phosphorylated by another Parkinsonian strongly 
associated protein, PINK1 [17]. The significance of this is as yet unknown, but it is interesting 
to note that both LRRK2 and PINK1 are linked to mitochondrial dysfunction and cytoskeletal 
reorganization [18], which as indicated above was how EFhd2 was also identified from 
proteomic screens in AD models.  
With respect to regulation of EFhd2 in AD, there have been reported differences, for 
example, whereas Borger et al. revealed a specific down-regulation of EFhd2 in the cortex, 
but not the hippocampus, of human dementia brains from different pathological traits, Ferrer-
Acosta showed that EFhd2 was up-regulated at the protein level in frontotemporal cortices of 
human AD patients [5]. The discrepancy between these two studies might be due to different 
extraction protocols. But Borger et al., revealed in addition to protein data also a 
transcriptional down-regulation of EFhd2 [6], thereby, supporting their protein biochemical 
data. However, it cannot be excluded that there are some forms of AD where EFhd2 is up-
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regulated. Larger study cohorts and even more comprehensive studies than have been 
performed [6] might be feasible in the future. 
Whereas the concomitant down-regulation of EFhd2 mRNA and protein specifically in 
the cortex of dementia patients suggests a tissue-specific transcriptional mechanism of efhd2 
gene regulation, additional post-translational mechanisms of EFhd2 regulation cannot be 
excluded. As mentioned above, in mice, the efhd2 locus is haplo-insufficient. Thus, one 
mechanism of regulation of efhd2 RNA expression could be heterozygously inherited or 
somatically acquired alterations of gene-regulatory elements in the efhd2 promoter/enhancer 
system. There might also be other mechanisms. For instance, neurodegeneration is associated 
with neuroinflammation [19, 20] and EFhd2 has been shown to be down-regulated under pro-
inflammatory conditions in peripheral blood monocytes (PBMC) from rheumathoid arthritis 
patients [21]. PBMC have recently been used to characterize neurodegenerative disorders [22, 
23] and Brachs et al. established a flow cytometric protocol to analyze EFhd2 expression in 
PBMC [9]. Tentatively, the regulation of efhd2 mRNA expression in neurodegeneration could 
be linked to inflammatory mediators targeting the as yet to be identified promoter/enhancer 
elements of the efhd2 locus. Indeed, efhd2 has been shown to be regulated by the PKCβ/NF-
κB pathway, with NF-κB being a classical pro-inflammatory stimulus, in mast cells [24]. To 
add another level of complexity, microRNAs (miRNAs) that regulate mRNA stability have 
been linked to amyloid production, tau phosphorylation, and inflammation in AD [25]. 
Nothing is known so far about miRNAs that could potentially regulate efhd2 expression 
during dementia. It is also not clear yet whether the reduction of efhd2 expression during 
neurodegeneration is reversible, causative, compensatory or functionally irrelevant. Inducible 
Efhd2 deletion or over-expression in a mouse model for neurodegeneration could address this 
question. 
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 Swiprosin-1/EFhd2 at the protein level 
At the protein level, EFhd2 consists of an N-terminal region of low complexity with an 
alanine stretch, a functional SH3 binding motif [26], two EF hands [27] and a C-terminal 
coiled-coil domain (CC) [27] (see also Figure 1). The unstructured N-terminal part has been 
shown to contribute to the strong thermal stability of recombinant EFhd2 [28]. The proline 
rich domain entailing amino acids 70 -79 is in fact a functional binding partner for the SH3 
domain of the src-like protein tyrosine kinase fgr [26]. Interestingly this binding depends on 
phosphorylation of EFhd2 and there are two serine residues in this region, S74 and S76, that 
have been described to be phosphorylated [29]. S74 has been shown to be phosphorylated by 
cdk5 [29] (for a comprehensive overview of EFhd2’s phosphorylation we refer to 
http://www.phosphosite.org). The SH3 domains of the src kinase lyn but not that of yes, and 
the SH3 domain of PLCγ bind EFhd2 but their binding sites in EFhd2 are not yet known [26]. 
EFhd2 has also been shown to bind Ca2+ [4]. Single amino acid mutations at critical polar 
amino acids predicted to be important in EF hands for Ca2+ binding due to their conserved 
positions (E116A, E152A, D105A, D141A), have demonstrated that both EF-hands are 
functional [28, 30]. Of note, by determining the affinity of EFhd2’s EF-hands by equilibrium 
centrifugation it has become clear that EFhd2 binds Ca2+ cooperatively, but with an affinity of 
only 68 μM [30]. Thus, Hagen et al. have proposed that EFhd2 is more like a Ca2+ sensor 
protein as it could bind Ca2+ only at higher concentrations, but then release it quickly. It is also 
possible that EFhd2 buffers strong Ca2+ transients temporarily. Hence, EFhd2 could modulate 
the spatiotemporal information of the second messenger Ca2+ (Figure 1). This notion is 
important as dysregulation of Ca2+ is involved in synaptic dysfunction in neurodegenerative 
and behavioural disorders [31, 32]. In that sense, phosphorylation of EFhd2 at S74 
(potentially by cdk5) [29] and a functional single nucleotide polymorphism (SNP), which is 
associated with AD (F89L)  [28], have both been shown to reduce EFhd2’s ability to bind 
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Ca2+ and could exert effects on EFhd2’s quaternary structure: The C-terminal coiled-coil 
domain mediates self-interaction of EFhd2 [5, 33], in a Ca2+ - dependent manner [33]. Ca2+ 
dependency for dimerization has, however, only been shown in one study [33]. This 
discrepancy might be due to different methods: whereas Ferrer-Acosta et al. used an ELISA-
like solid phase interaction assay [5], Kwon et al. tested the dimerization capacity in solution 
and by co-immunoprecipitation from extracts of transfected cells [33]. In conclusion, EFhd2 
might interact weakly in the absence of Ca2+, which could be detected in solid phase binding 
assays, and more strongly in the presence of Ca2+.  However, as the affinity of EFhd2 for Ca2+ 
is low, the dimeric forms of EFhd2 are expected to form at a low rate or only transiently. A 
very similar CC domain is also present in the EFhd2 orthologue EFhd1 [27], but so far there 
is no reported evidence for hetero-dimerization of EFhd2 and EFhd1 by co-
immunoprecipitation analysis of endogenously expressed proteins [9]. The CC domain has 
also been reported to mediate the interaction of EFhd2 with a mutant form of the microtubule 
associated protein (MAPT) tau (tauP301L) in tau transgenic brain extracts [5]. Here, it is not 
clear whether dimerization of EFhd2 through the CC domain exposes a tau binding domain of 
EFhd2 or whether EFhd2 binds mutant tau directly through its CC domain. Dimerization of 
EFhd2 through its CC domain is mediated by a lysine-rich stretch [33]. Mutant tau isoforms, 
such as tauP301L, are usually highly phosphorylated [34]. One possibility could be that the 
positively charged Lysine rich stretch in the CC domain of EFhd2 binds negatively charged 
tau residues. If Ca2+ induces EFhd2 dimers via the CC domain, it could be possible that the 
EFhd2-tau interaction site is blocked. Thus, Ca2+ induced dimerization could regulate the 
observed tau-EFhd2 interaction negatively. In the future, it will be interesting to know 
whether monomeric or dimeric EFhd2 binds to wildtype tau or tau P301L, especially with 
respect to the proposed amyloid structure of recombinant EFhd2 [5]. EFhd2 binds also 
directly to F-actin, in a Ca2+ independent manner, and has three F-actin binding regions [aa 
69-84, aa 96-163, aa 163-199] [marked in red in Figure legend 1].   
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Regulation of Actin dynamics by EFhd2  
a. Cofilin 
EFhd2 has been shown to regulate the accessibility of the actin severing protein cofilin to F-
actin and it induces F-actin bundling [33, 35]. Brachs et al. showed that in B cells, genetic 
knockout of EFhd2 enhanced the dephosphorylation of cofilin at S3, i.e. its activation, after B 
cell receptor stimulation of resting B cells [8]. Hence, deletion of EFhd2 is expected to have a 
profound effect on local actin stability by regulating the activity of cofilin at several levels: 
firstly, by competing with it for F-actin binding [35]; secondly, by regulating its 
dephosphorylation on S3 and therefore its activity, at least in B cells [8]. The 
dephosphorylation of cofilin is regulated by increases in the intracellular Ca2+ concentration; 
for instance after B cell receptor (BCR) [36] or epidermal growth factor receptor (EGFR) 
activation, leading to activation of the phospholipase-inositol-tris-phosphate (PLC-IP3) 
pathway. EGF stimulation induced phosphorylation of EFhd2 on S138 in transfected 293 cells 
[35]. Another group has shown that EGF can reversibly dephosphorylate EFhd2 on Y83 in 
HeLa cells with the same kinetics as proteins involved in actin dynamics, namely gelsolin and 
arp2/3 [37]. Increased intracellular Ca2+ elicited by the PLC-IP3 pathway activates two protein 
phosphatases, calcineurin and slingshot, which dephosphorylate cofilin [38]. Enhanced 
dephosphorylation of cofilin in BCR-activated EFhd2-deficient B cells [8] and putatively 
other cell types after stimulation with other agonists might be explained by a locally increased 
Ca2+ concentration because EFhd2’s buffering capacity is missing, leading to increased 
phosphatase activity. Interestingly, EGF activates the calcineurin signaling pathway followed 
by a transient increase of cofilin at the leading edge allowing for neurite outgrowth [39-41]. 
Modulation of EGF elicited cofilin activity by EFhd2 might therefore play a role in neurite 
outgrowth of primary cortical neurons [42]. Deduced from the published data, one would 
assume that as soon as the local Ca2+ concentration is high enough (in the micromolar range; 
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[8]), F-Actin bound EFhd2 could dimerize, bundle F-actin and prevent cofilin from actin 
severing (Figure  1). This is expected to be a dynamic process due to the low affinity of 
EFhd2 for Ca2+ but could allow for the stabilization of actin-dependent signalling or 
membrane complexes, thereby, impacting longer lasting responses mediated by, for instance, 
growth factors or synaptic Ca2+ oscillations. Whereas wildtype EFhd2 or a S138A mutation 
inhibit cofilin activity in vitro and in transfected B6F10 melanoma cells, the phospho-mimetic 
mutant S138E does not. Hence, EGF leads to local de-stabilization of F-actin through a 
phosphorylation of S138 in EFhd2 [35]. The EGF-induced phosphorylation of EFhd2 on Y83 
and Y104, with Y104 being in the first EF-hand domain, appear to be irrelevant for this 
process [35]. However, both S138A and S138E mutations disturbed the localization of cofilin 
at the leading edge of EGF-elicited lamellipodia, and lamellipodia dynamics. Hence, a 
dynamic equilibrium of EFhd2 phosphorylation regulates likely cofilin activity and 
localization, which is required to provide a pool of G-actin endowing dynamic assembly of F-
actin. F-actin assembly and branching are important for formation of filopdia and 
lamellipodia and are up-stream of cofilin, generally controlled by a family of small Ras-like 
GTPases comprising Rho, Ras, Rab, Arf, Sar and Ran proteins [43]. In particular the Rho and 
Ras members play critical roles during all stages of axonogenesis [44]. EFhd2 is expressed in 
dendrites, axons and synapses and knock-down of Efhd2 increases pre-synaptic densities [6, 
7]. It has to be noted that at first glance and macroscopically, brains of EFhd2KO mice appear 
to be normal. However, deletion of EFhd2 might have very specifically localized effects on 
one of these GTPases - Cdc42, Rac and Rho - within the neuron or even within specific 
subtypes in vivo, which might explain the effects on axonal transport ([7]; see below) or pre-
synaptic plasticity [8]. In the following section, we will therefore discuss the published 
involvement of EFhd2 in the regulation of small GTPase activity and put it into the context of 
axonogenesis. 
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b. Small GTPAses and Axonogenesis 
 Axonogenesis is important during brain development and regeneration after traumatic or 
disease induced injury, such as in neurodegenerative disorders (for review please see [45, 
46]). Of note, axonogenesis is a differentiation process. It is likely that there is a coordinate 
regulation between migration of neuronal stem cells during development and regeneration, 
and their differentiation [46]. Axonogenesis does require a close interplay between the actin 
and microtubule (MT) systems. Both migrating and differentiated neurons are polarized, with 
the MT organizing center (MTOC; also called centrosome) directed into the direction of 
movement. Directed movement is dictated by the growth cone, that in itself, becomes 
instructed by axon guidance signals and is a dynamic region rich in F-actin [46]. The actin 
cytoskeleton plays a major role in pathfinding. The MT cytoskeleton, on the other hand, 
provides structure to the axon shaft and MT-actin interactions are fundamental for axon 
extension. Specifically, the plus end of MT is attached to actin structures in the growth cone, 
which also influence MT growth mechanically. In particular, MT extension occurs 
preferentially along filopodia [45]. Interestingly, the filopodia are composed of bundled F-
actin and are sensors of guidance cues [47].  It remains to be determined whether and where 
EFhd2 exhibits F-actin bundling activity in neurons. One possibility could be within 
filopodia, particularly in light of EFhd2’s regulation of Cdc42 activity (see below). Whereas 
filopodial bundles attract the plus ends of MT and also transport MT, the growth cone 
contains, in addition, transverse actin bundles (also called actin arcs) that restrain MT from 
attaching [45]. It has been proposed that the distal MT position is controlled by the rate of 
plus end assembly and retrograde actin flow [48]. Besides mechanical mechanisms there is 
also a plethora of proteins that interact specifically with both the MT and the actin 
cytoskeleton, regulating their dynamic interaction, such as cofilin and tau and now also 
EFhd2 (Figure 1), which are all involved in controlling axon growth [49, 50]. MT extending 
with their plus ends towards the growth cone are linked there to the dynamic actin structures 
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through complexes of linker proteins, such as the PAFAH1B1-CLIP170-Cdc42-Rac complex 
[46]. Proteins such as PAFAH1B1 promote both MT and actin dynamics, thereby, connecting 
MT to newly formed protrusions in the growth cone of the axon [46]. Attracting or repelling 
extracellular signals, such as elicited through the Reelin pathway, Semaphorins or NoGo 
transmit signals via specific receptors, such as LRP8, to ultimately control activation of small 
GTPases, such as Cdc42/Rac/Rho  [46].  
 Small GTPases cycle between an active, GTP bound state and an inactive, GDP bound 
state.  GTP exchange factors (GEFs) activate GTPases by catalyzing the exchange of GDP for 
GTP, whereas GTPase activating proteins (GAP) inactivate these small GTPases by 
increasing their GTPase activity. GTP-loaded GTPases bind many down-stream effector 
proteins of various signalling pathways, amongst them effectors regulating actin and 
microtubule assembly, such as PAK (p21 activated kinase) or WAVE proteins [43]. The Rho 
and Ras members are involved in initiation, elongation, guidance and branching of axons [44]. 
Their main function is to regulate the interaction of the growing axon with other cells and 
extracellular matrix. They also control the delivery of cargo to the axon through the exocytic 
machinery, and they are involved in the internalization of membrane and proteins at the 
leading edge of the growth cone through endocytosis [44]. Asymmetric transport of proteins 
to the axon is important for maintenance of neuronal polarity. Cdc42 is important for neuronal 
polarization and Rac regulates pathways that regulate microtubule growth in the developing 
axon [51]. Conditional deletion of Cdc42 reveals normal initial neurite sprouting but axon 
formation was strongly impaired [52]. As in many systems, Rho appears to be antagonistic in 
axon specification towards Cdc42 and Rac by activating ROCK (Rho activated coiled-coil 
kinase) [53]. In contrast to axon initiation, axon elongation can, however, also be positively 
regulated through the SDF1-α/Rho/mDia pathway [54]. Interestingly, SDF1-α elicited 
spreading of Jurkat cells overexpressing a EFhd2-GFP fusion protein is enhanced, indicating 
that EFhd2 can amplify SDF-1α signals through an yet to be identified pathway [33].  The 
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regulation of the Cdc42, Rac and Rho pathways appears to be involved in nerve regeneration 
as well. For instance, TC10, a close relative of Cdc42, was initially identified in neuronal 
cells as a gene that was dramatically re-expressed after axotomy of motor neurons in the 
hypoglossal nuclei [55]. Both Rho and Pak (which is downstream of Rac) can inhibit cofilin 
through Lim kinase 1 [44]. Thus, Rac may limit axon growth through this pathway, but may 
also activate it through another effector, STEF [56]. In any case, it is clear that cofilin 
phosphorylation and dephosphorylation are important in axonal outgrowth. Moreover, Rho 
and ROCK often, but not always, play antagonistic role in axon outgrowth and guidance 
towards Rac and Cdc42, which provide attractive cues and forward protrusion [44].  
Plating CHO-K1 cells on fibronectin revealed that overexpression of an EFhd2-GFP 
protein enhances basal and fibronectin-induced Rac activity [33]. Likewise, B6F10 melanoma 
cells stably over-expressing an EFhd2-GFP fusion protein revealed basally increased Rac and 
Cdc42 activity but reduced Rho Activity. In contrast, shRNA mediated silencing of EFhd2 in 
B6F10 cells increased Rho activity [33]. Thus, EFhd2 appears to be antagonistic towards Rho, 
and to activate Cdc42 and Rac. In accordance, increased membrane ruffling induced through 
overexpression of EFhd2-GFP could be reduced by simultaneous expression of dominant-
negative Rac and conversely, reduction of membrane ruffling by shRNA against EFhd2 was 
reverted by dominant-negative Rac [33]. Interestingly, silencing of EFhd2 prevented transwell 
invasion of B6F10 melanoma cells induced in vitro through constitutively active Rac and 
enhanced invasion prevented through constitutively active Rho [33]. These results indicate 
that EFhd2 can function upstream of Cdc42, Rac and Rho, but can also modulate the effector 
functions of these small GTPases. This mechanism may relate to modulation of cofilin 
activity by EFhd2 but other mechanisms cannot be excluded. In total, EGF-induced 
phosphorylation of EFhd2 resulted in loosening of F-actin bundles. Thereby, cofilin gained 
more access to F-actin at the leading edge, and cofilin activity led to the generation of short 
actin filaments with free barbed ends [33]. This may alter actin dynamics. In light of these 
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data it is intriguing that actin and cofilin mediated actin remodelling appear to be important 
for synaptic plasticity [57, 58] .   
In summary, we conclude from biochemical data that EFhd2 has the potential to 
transmit Ca2+ transients into the regulation of actin stability (Figure 2). This function of EFhd2 
could have profound pleiotropic effects in many systems. It is not clear which receptors and 
GEFs are up-stream of EFhd2-regulated GTPase activation and effector function within the 
brain, but SDF-1α or EGF might play a role. As EFhd2 appears to regulate F-actin bundling, 
too, it might well exert pleiotropic effects. For instance, Semaphorin3A leads to the activation 
of Rho and ROCK, and attenuates actin polymerization, while promoting intra-axonal F-actin 
bundling and myosin II-mediated force generation [59]. More specifically, as EFhd2 is down-
regulated in Nogo-A knockout neurons, which reveal an increased regeneration potential [60], 
it could mediate the inhibitory effects of Nogo. The Nogo receptor mediates the inhibitory 
effects of Nogo-A, MAG, and OMgp on neurite outgrowth [61] by activating Rho and 
decreasing Rac activity. Loss of EFhd2 could shift this equilibrium.  Down-regulation of 
EFhd2 in the cortices of dementia patients could therefore be a rescue pathway, by blocking 
the function of inhibitory receptors. 
 
Function of EFhd2 in primary neurons: synapses and intracellular transport 
EFhd2 is expressed in cortical neurons and its expression appears to be biphasic when 
neurons are allowed to culture in vitro [7]. At the sub-cellular level, Efhd2 has a discrete 
punctate distribution which was shown to co-stain along neurites with MAP2 and tau, 
potentially hinting at it being involved in vesicle transport, and it was partially located at 
synaptic regions co-staining with synapsin 1a/b and closely associated with PSD95. The 
specific and significant change in the EFhd2 protein levels in dementia leads to ask the 
question what does EFhd2 do and is this down-regulation of expression important for the 
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biochemistry and physiology of the neuron? Recent studies have now indicated that EFhd2 
may have roles in both synapses and intracellular transport.  
   The synaptic presence of EFhd2 was confirmed by biochemical analysis of isolated 
synaptosomes [6, 7]. As described above, physiologically in various types of dementia there is 
a decrease in the amount of both protein and mRNA levels of EFhd2 [6], though intriguingly 
this only appears to occur in the cortex regions and not the hippocampus. It is also of note that 
there is also no difference in EFhd2 levels whether the dementia has underlying tau pathology 
[6]. The decrease in the protein levels of synaptogenic EFhd2 would suggest a potential 
phenotypic change in neuronal behaviour. Initially and possibly surprisingly, the removal of 
EFhd2 appeared to have no effect on the activity of synapses as there were no reported 
differences in electrophysiologically stimulated release of synapto-phluorin from transfected 
primary neurons derived from EFhd2KO as compared to wildtype mice [7]. However, there 
was a significant difference in the number of synapses that could be formed, i.e. a decrease in 
EFhd2 expression led to the production of more synapses [6]. Given the ability of the frontal 
cortex to respond to the onset of dementia by neuronal reorganization [62], the regulation of 
EFhd2, be it on the RNA or protein level, could allow a challenged cortical neuronal circuit 
system to cope with damage. It is tempting to speculate that these hypothetical remodeling 
mechanisms function through EFhd2’s functions in the Cdc42/Rac/Rho/Cofilin pathways (as 
outlined above); or its function in kinesin-mediated microtubule gliding (outline below) [7]; 
or in a dynamic exchange between the actin and MT system (Figure 3).  
Neurofibrillary tangles (NFT) but not senile plaques parallel duration and severity of 
AD [63]. Hence, a critical issue appears to be the amount and phosphorylation status of the 
tau protein: even moderate overexpression of wildtype tau can induce neurodegeneration, 
possibly by interfering with kinesin-mediated transport of mitochondria, vesicles and 
endoplasmatic reticulum [64, 65]. It does so by limiting distance travelled by cargo and also a 
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reduction in multiple-kinesin velocity [66]. Hyperphosphorylated tau that relocalizes to the 
somatodendritic compartment disrupts normal axonal transport massively by trapping the 
kinesin adapter-molecule JIP1 (Jun N-terminal kinase interacting protein 1; now called 
MAPK8IP1] in the soma [67, 68]. JIP1 would normally interact with Doublecortin (DCX), 
thereby, also controlling actin dynamics in the growth cone [69]. Thus, tau malfunction 
impacts also the actin cytoskeleton. A physiologic function of tau, however, appears to be the 
stabilization of microtubules to control axonal transport, which is negatively regulated by 
phosphorylation, but reversible and controlled phosphorylation of tau are as well be important 
for synaptic plasticity [34, 70]. Interestingly, alterations in intracellular endo-lysosomal 
vesicle transport as well as autophagy appear even to precede Amyloid beta (Aβ) and tau 
pathology [71]. In light of these findings, it is therefore intriguing that we have previously 
shown that kinesin (KIF5A)-induced MT gliding was decelerated by the addition of a GST-
EFhd2 fusion protein to this system, indicating a dose-dependent functional interaction 
between EFhd2 and KIF5A [7]. Therefore, we proposed that a potential mechanism of the 
interference with kinesin activity towards MTs could be inhibition of MT binding to kinesin 
by EFhd2 (Figure 2). Of note, neurite outgrowth and axonal re-generation of Drosophila 
neurons have been proposed to be mediated by kinesin-mediated microtubule gliding [72, 73].   
Thus, down-regulation of EFhd2 could foster synaptic delivery through kinesin-
mediated transport, an idea that is supported by Borger et al.’s finding of increased pre-
synapse formation in EFhd2 knock-down neurons [6]. It is therefore reasonable to assume that 
EFhd2 is linked to intra-neuronal transport and dementia, which would support hypotheses of 
alterations in the endo-lysosomal vesicle transport system as being involved in 
neurodegeneration [74-76]. Given the reported interaction of EFhd2 and tauP301L [4] it is 
striking that both proteins inhibit kinesin-mediated transport independently [7, 77]. It is even 
more striking that both EFhd2 and tau exhibit F-actin bundling activity [78], that actin 
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dynamics are altered in tauopathies [77] and that EFhd2 was found in synapses [6, 7]. A 
locally increased concentration of EFhd2 in synapses could thus serve to stop axonal transport 
and to place cargo correctly – in synapses (Figure 3). On the other hand, a local Ca2+ 
transient, for instance induced through an action potential, could foster synaptic stabilization 
by aiding Ca2+-controlled EFhd2 dimerization and F-actin bundling – putatively in filopodia 
or arcs composed of bundled F-actin. If the EFhd2 concentration was limiting, kinesin-
mediated transport could then resume, thereby, replenishing used-up cargo. Moreover, there 
might be pools of EFhd2 shuttling between the microtubule and actin system, depending 
perhaps on the local Ca2+ concentration (Figure 3).  It is thus tempting to speculate that loss of 
EFhd2 could modulate long term potentiation by modulating delivery of kinesin-transported 
cargo and by orchestrating local actin dynamics in a dynamic equilibrium. 
 
Putative amyloid structures of EFhd2 and their possible function 
Intracellular transport along microtubules and axon formation under control of actin-
membrane dynamics is required for delivery of vesicles and mitochondria to synapses. Vice 
versa, this system is also required for intracellular waste disposal and recycling. The hallmark 
of many dementias is the occurrence of intra-and extracellular aggregates of misfolded 
proteins. Especially deposits of tau have been intensively characterized for many years [79].   
Two main degradation pathways for tau exist: autophagy and the proteasome [80]. 
Both degradation pathways appear to be possible targets for the treatment of AD [81, 82]. 
Autophagy is a lysosomal survival pathway and regulates degradation and recycling of 
damaged organelles and cytoplasmic proteins, which appears to be specifically important in 
neurodegenerative diseases [83, 84]. In chaperone mediated autophagy (CMA), Hsc70 binds 
proteins with exposed KFERQ motifs and delivers them to lysosomes through LAMP-2A 
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(Lysosome-associated membrane protein type 2A) [85]. The tau complexes Vega et al. had 
purified from JNPL3 mice did not only contain EFhd2 but also Hsc70 [4], which controls 
CMA [85]. Hence, EFhd2 could be involved in CMA and removal of pathologic tau isoforms. 
On the other hand, EFhd2 co-localizes with hyperphosphorylated tau in AD brain, with Aβ-
bearing neurons and recombinant EFhd2 can be rendered an amyloid protein itself as shown 
by electron microscopy [5]. In addition, Thioflavin S binding in the presence and absence of 
Heparin has revealed extensive β-barrel sheets in EFhd2 [5]. Whereas the authors interpreted 
their finding as evidence for amyloid EFhd2 being putatively dangerous, EFhd2 as a 
component of insoluble tau or Aβ aggregates could as well be a harmless or even beneficial 
“off pathway” side-product, perhaps from CMA, as tau-tangle bearing neurons can also be 
long-lived [86] .  
 
Concluding remarks 
The observed down-regulation of EFhd2 in dementia might have opposing functions and its 
mechanism is unknown. Thus, the function of EFhd2 in neurodegeneration has to be further 
elucidated, probably with inducible knockout or transgenic EFhd2 mouse models in a 
neurodegenerative background. It will also be important to analyse more dementia patients 
across different intercontinental cohorts for EFhd2 expression. One facilitation in this process 
might be the analysis of PBMC for EFhd2 expression. As EFhd2 has been shown to modulate 
F-actin bundling, cofilin activity and Cdc42, Rac and Rho activity, a special interest lies on 
the investigation of these pathways in primary neurons, specifically in synaptic plasticity. In 
addition, nothing is known about the growth factors, intercellular signals, receptors and GEFs 
that are up-stream of EFhd2’s ability to regulate small GTPases. Amongst others, Nogo-A, 
EGF or SDF-1α might, however, be interesting candidates as they are involved in small 
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GTPase signaling, neurite development and plasticity. Another system to focus on is kinesin- 
mediated transport along microtubules, which is partly also organized by small GTPases. 
Taken together, these investigations will help to understand the significance of the regulation 
of EFhd2 in the cortex of dementia patients. 
 
Figures 
Legend  
Schematic of the proteins and molecules represented in Figures 1-3. Proteins and Ca2+ ions 
are not drawn to scale. The F-Actin binding domains of EFhd2 are highlighted  in red. EF, EF hand; 
CC, coiled-coil domain. G-Actin, globular actin. 
 
Figure 1 Transmission of Ca2+ signals and regulation of F-Actin stability through EFhd2 
Depending on the local  Ca2+ concentration EFhd2 shuttles between monomeric and dimeric 
states. Due to to low affinity of EFhd2 for Ca2+ this is expected to be a dynamic process. 
Enhancement of Rac and Cdc42 activity through EFhd2 leads to local Actin polymerization. 
F-Actin bound by EFhd2 through its F-Actin binding domains (marked in red) will be 
bundled at higher Ca2+ concentrations. EFhd2 mediated F-Actin bundling prevents access of 
Cofilin to F-Actin which stabilizes F-Actin locally. F-Actin polymerization and bundling 
through EFhd2 could stabilize pre-synaptic structures. The signals leading to EFhd2 mediates 
Rac and Cdc42 activation in neurons remain to be identified. 
 
Figure 2 Regulation of kinesin mediated transport along microtubules by EFhd2. 
Recombinant EFhd2 inhibits kinesin-mediated microtubule gliding in vitro. Knock-out of 
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EFhd2 increases the velocity of kinesin mediated transport of a synaptic protein, 
synaptophysin in primary neurons. Knock-down of EFhd2 in primary neurons increases the 
formation of pre-synaptic densities. Thus, the local concentration of EFhd2 may regulate 
controlled delivery of cargo. Either overepxression or loss of EFhd2 may lead  to displaced 
presynaptic cargo.  
 
Figure 3 Bidirectional regulation of kinesin mediated transport and actin dynamics 
through EFhd2 in presynaptic compartments 
a) In the absence of EFhd2, a local increae in Ca2+ might  be less translated into F-Actin 
stabilization, Concomitantly, kinesin-mediated transport increases and gets delivered into 
a relative flexible pre-synaptic compartment. 
b) When the local Ca2+ concentration increases in the presence of EFhd2, F-Actin becomes 
bundled by EFhd2 and, thereby, stabilized. Whether this affects transport of cargo along 
microtubules in not known, but a pool of EFhd2 might be stabilized at F-Actin and be less 
accessible at microtubules. 
c) In the presence of EFhd2 and with low intracellular Ca2+ kinesin-mediated transport on 
microtubules occurs normally, F-Actin is accessible to Cofilin, not bundled by EFhd2 and 
therefore  more flexible. 
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